Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.02+0.02 (+0.67%)
Close on Nov 17, 2026Market cap $70.84MP/E –Yield –
Coya Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Coya Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.64M, up 64.9% year over year. For fiscal 2025 it was $16.73M, up 41.0% from the year before. The highest annual figure on record is $16.73M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.73M | +41.0% |
| FY2024 | Dec 31, 2024 | $11.87M | +115.7% |
| FY2023 | Dec 31, 2023 | $5.50M | +24.7% |
| FY2022 | Dec 31, 2022 | $4.41M | +73.6% |
| FY2021 | Dec 31, 2021 | $2.54M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.57M | +193.8% |
| Q2 FY2026 | Jun 30, 2026 | $5.03M | +37.3% |
| Q1 FY2026 | Mar 31, 2026 | $4.10M | -21.4% |
| Q4 FY2025 | Dec 31, 2025 | $4.94M | +155.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.92M | +31.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.66M | -19.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.21M | +66.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.94M | +20.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.22M | +39.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.57M | +327.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.14M | +154.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.61M | +127.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.59M | +24.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.07M | -26.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.23M | +25.8% |
| Q4 FY2022 | Dec 31, 2022 | $708.03K | – |
| Q3 FY2022 | Sep 30, 2022 | $1.28M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.45M | – |
| Q1 FY2022 | Mar 31, 2022 | $978.80K | – |
See a number that looks wrong?